All News

Forrest N. Ridgway, PharmD, BCOP, discusses health misinformation, AI-generated medical advice, wellness culture, and the controversial therapies patients are bringing into the clinic.

Effective real-world management of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) is critical to safely delivering CAR T-cell therapies and bispecific antibodies.

Advanced lung cancer inflammation index (ALI) predicts 3‑month recovery after thrombolysis for acute ischemic stroke, with low ALI signaling higher risk.

University of Arizona pharmacy interns who received mentorship and engaged in pharmacist-level tasks report greater satisfaction and perceived professional readiness, highlighting a need to restructure internships as longitudinal, competency-based experiences.

Joseph Saseen, PharmD; and Joel C. Marrs, PharmD, discuss key updates in the 2026 dyslipidemia guidelines and their implications for clinical and pharmacy practice.

Some pharmacists are exploring the possibilities of moving to New Zealand for better work/life balance.

A new study describes the high symptom burden carried by pediatric long COVID patients and highlights integrative medicine's role in their care.

GLP-1 weight-loss drugs reshape healthcare and consumer spending, as markets surge, coverage splits, and subscription models spread.

In this debut episode Erica Marini and her colleagues discuss the critical role pharmacists play in complex neurologic care and the latest emerging therapies and research presented at the AAN 2026 Annual Meeting.

The World Health Organization confirmed the outbreak is the Andes strain, the only known human transmissible hantavirus.

The agency greenlit 4 Glas electronic nicotine delivery systems through the premarket tobacco product application pathway, a historic first that comes amid reported White House pressure on FDA Commissioner Marty Makary.

FDA leaders reportedly delay vaccine safety findings on COVID-19 and shingles shots, raising transparency concerns and new challenges for pharmacists.

The ACCESS trial found that expanding hematopoietic cell transplant eligibility through mismatched unrelated donors increased racial, ethnic, and socioeconomic diversity among recipients.

Study data show that extended endocrine therapy after 5 years reduces late recurrence in premenopausal breast cancer, with benefits varying by tumor subtype.

Emerging synthetic opioids known as orphines are entering the illicit drug supply with extreme potency and detection challenges.

Expanding education, safety responsibilities, and patient support roles are elevating the importance of pharmacy technicians in cancer care.

Discover how pharmacists guide women through sensitive health needs, improving outcomes in every community.

The initiatives have intensified discussion surrounding the use of SSRIs, their discontinuation, and broader approaches to mental health care.

Pharmacists guide evidence-based medication care as AI, regulation shifts, and new therapies rise.

A strategic framework for pharmacists to successfully appeal prior authorization denials through evidence-based documentation, proper coding, and systematic follow-up to ensure patient medication access.

ENVISION trial shows mitomycin intravesical solution after TURBT delivers durable control in recurrent NMIBC, with 72% event-free at 24 months.

Education, safety protocols, and evolving responsibilities are transforming the role of pharmacy technicians in cancer care.

Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on how pharmacy technicians can recognize when patients should be referred to a pharmacist or physician instead of self-treating with OTC products, and how to help patients avoid risks associated with combination products such as duplicate ingredients.

Bispecific antibodies show strong efficacy in relapsed/refractory lymphoma and early promise in frontline combination settings.

A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.

New findings presented at the World Congress of Nephrology detail how chronic kidney disease (CKD) drives progressive muscle loss and cognitive decline.

New CMS prior authorization timelines highlight major infrastructure gaps while underscoring the link between access, affordability, and medication adherence.